Riddhi Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.20 Cr
as on 26-06-2024
- Paid Up Capital ₹ 0.93 M
as on 26-06-2024
- Company Age 29 Year, 26 Days
- Last Filing with ROC 31 Mar 2023
- Revenue -53.73%
(FY 2022)
- Profit -54.81%
(FY 2022)
- Ebitda -166.04%
(FY 2022)
- Net Worth -16.76%
(FY 2022)
- Total Assets -1.13%
(FY 2022)
About Riddhi Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.20 Cr and a paid-up capital of Rs 0.93 M, as per Ministry of Corporate Affairs (MCA) records.
Pravin Jain, Rahul Jain, and Abhay Jain serve as directors at the Company.
- CIN/LLPIN
U24230MH1995PLC094749
- Company No.
094749
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
24 Nov 1995
- Date of AGM
15 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Riddhi Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abhay Jain  | Director | 10-Mar-2014 | Current |
| Pravin Jain | Director | 10-Mar-2014 | Current |
| Rahul Jain | Director | 10-Mar-2014 | Current |
Financial Performance and Corporate Structure Insights of Riddhi Pharmaceuticals.
Riddhi Pharmaceuticals Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 53.73% decrease. The company also saw a substantial fall in profitability, with a 54.81% decrease in profit. The company's net worth observed a substantial decline by a decrease of 16.76%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Riddhi Pharmaceuticals?
In 2021, Riddhi Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Uttaranchal Biotech LimitedActive 19 years 3 monthsPravin Jain, Rahul Jain and 1 more are mutual person
Surajlok Chemicals Private LimitedActive 33 years 10 monthsPravin Jain, Rahul Jain and 1 more are mutual person
Korten Pharmaceuticals Private LimitedActive 34 years 1 monthPravin Jain and Rahul Jain are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Riddhi Pharmaceuticals?
Unlock and access historical data on people associated with Riddhi Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Riddhi Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Riddhi Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
